Clinical Trial Update: Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

View source ↗

Summary

Tiziana Life Sciences reports an expanded-access update for Foralumab in non-active secondary progressive multiple sclerosis, expanding the intermediate-size pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• Foralumab (Foralumab)

Snippet

Sponsor: Tiziana Life Sciences LTD | Conditions: Non-Active Secondary Progressive Multiple Sclerosis | Status: AVAILABLE